Conclusion: This systematic review identifies the state and mechanism of action of emerging pharmacotherapies undergoing or having completed phase 2 and phase 3 clinical trials. The information provided herein furthers the understanding of obesity management, implying direct clinical implications and stimulating research initiatives.
PubMed 39952695 ↗Retatrutide
Also known as LY3437943
The short answer. Most people who report on Retatrutide say it helped (76% of 327). It is most often used for weight loss: 92% of 228 reports say that improved. There is a moderate body of research — 22 meta-analyses and 6 trials. The most common complaint is nausea. It is not an approved supplement and carries real risks.
From 460 mentions in total — the rest didn't say how it went and aren't counted.
What Retatrutide does, according to users
Of the people who reported each effect, the share who said it got better.
1 more with fewer than 3 reports
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
At least one meta-analysis, or 5+ randomized controlled trials. The grade measures how much human research exists — read the conclusions below for what it found. 22 meta-analyses on PubMed ↗ · 6 randomized trials ↗
Conclusion: GLP-1 RAs and co-agonists are efficacious for weight loss, with reported safety concerns predominantly gastrointestinal in nature, when used among adults with overweight or obesity and without diabetes.
PubMed 39761578 ↗Conclusion: GLP-1 RAs carry a slightly increased risk of pancreatitis, which is not significant when stratified by background medication use. Overall risk for pancreatic cancer was not observed, but a slight association was found when stratified with background medications. However, this difference is likely minimal, given the numerous studies excluded from the meta-analysis where both treatment arms had zero events.
PubMed 40988099 ↗Conclusion: Retatrutide (both doses) and tirzepatide exhibited superior efficacy compared to other GLP-1 receptor agonists and polyagonists in reducing body weight and waist circumference. Patients without T2DM, those with a high BMI, and individuals undergoing longer treatment cycles demonstrated significantly greater weight loss and reductions in waist circumference. Dual or triple receptor agonists (GLP-1 plus glucose-dependent insulinotropic polypeptide and/or Glucagon receptor) are more effective for weight loss than GLP-1 receptor agonists.
PubMed 39305981 ↗33 human trials on ClinicalTrials.gov test Retatrutide — 21 completed, 2 recruiting now. See all on ClinicalTrials.gov ↗
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight · Obesity, Overweight · 2026
- A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease · Obesity, Cardiovascular Diseases · 2026
- A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight · Type 2 Diabetes, Obesity · 2026
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
NIH has funded 1 research project with Retatrutide in the title, $372,400 in total (2025–2025). NIH RePORTER ↗
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“Drastically reduced appetite: At 5mg, I experienced near-total suppression of hunger and cravings. Steady, effortless fat loss: I didn't have to track macros obsessively or do extreme cardio.”
“I’ve tried Reta and it melted fat away at 1mg - I really disliked the increased heart rate (and it was only 8bpm) and the nuking of my HRV.”
“Once I started Reta at 2mg in January, it completely changed my mindset.”
“I lost 115 lbs in the last year (260 → 145)...retatrutide seemed to finally address my insulin resistance.”
Top discussions (5)
Retatrutide compared
Other options for weight loss
Sources
- User reports: 460 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- NIH RePORTER ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate